Antidepressant Efficacy and Cardiovascular Safety of Venlafaxine in Young Vs Old Patients with Comorbid Medical Disorders
| Autor: | Debbie Zeiler, Mary Brilmyer, Ben Zimmer, Ravi Kant |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Adolescent Diastole Hemodynamics Blood Pressure Venlafaxine Comorbidity Norepinephrine (medication) Risk Factors medicine Humans Depression (differential diagnoses) Aged Aged 80 and over Depressive Disorder Major Dose-Response Relationship Drug Mood Disorders business.industry Venlafaxine Hydrochloride Middle Aged Cyclohexanols medicine.disease Cerebrovascular Disorders Psychiatry and Mental health Blood pressure Cardiovascular Diseases Anesthesia Ambulatory Antidepressive Agents Second-Generation Major depressive disorder Female business medicine.drug |
| Zdroj: | The International Journal of Psychiatry in Medicine. 27:353-364 |
| ISSN: | 1541-3527 0091-2174 |
| DOI: | 10.2190/udrd-99cb-t6kh-edkp |
| Popis: | Objective: To determine whether venlafaxine exerts a differential effect on blood pressure in young versus old depressed patients. Method: We compared thirty-four consecutive patients treated with 50–250 mg/day venlafaxine for major depressive disorder or another major mood disorder at our medical college's ambulatory neuropsychiatry program. We obtained baseline and follow-up blood pressure measurements. Each patient also received a baseline and final Clinical Global Impressions (CGI) score; global improvement was determined by consensus of two clinicians. Results: Sixteen nongeriatric patients (age, 13 to 56 years) were compared with eighteen elderly patients (age, 65 to 86 years). Most patients (88%) had serious medical comorbidities or histories. Despite a higher mean daily venlafaxine dosage for patients in the young group, no significant changes in systolic blood pressure were noted in either group. For the older group, we found a non-statistically significant 4.7 mm Hg mean increase in diastolic blood pressure. No patient became hypertensive. We also found a negative correlation between baseline diastolic blood pressure and change in diastolic blood pressure during treatment with venlafaxine. This inverse relationship was statistically significant in the older patients. Conclusions: Venlafaxine was not associated with significant, sustained changes in blood pressure in any patient receiving dosages of 50–250 mg/day. Minimal changes in diastolic blood pressure were no more likely to occur in older venlafaxine-treated patients than in younger ones. Higher baseline diastolic blood pressure in older patients, but not in younger ones, seemed to protect against diastolic adrenergic blood pressure effects of venlafaxine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|